Recently, a combination of MPL and CpG, a TLR9 agonist, immunized with influenza split vaccine elicited strong antigen-specific Th1 immune responses and induced protective efficacy against homosubtypic and heterosubtypic influenza infections [17,18]. Here, TLR9 is linked to influenza.